Jorge Joven

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8497468/publications.pdf

Version: 2024-02-01

389 papers 13,534 citations

62 h-index 92 g-index

404 all docs

404 docs citations

404 times ranked 19252 citing authors

#	Article	IF	CITATIONS
1	An <scp>MMP</scp> â€degraded and crossâ€linked fragment of type <scp>III</scp> collagen as a nonâ€invasive biomarker of hepatic fibrosis resolution. Liver International, 2022, 42, 1605-1617.	1.9	9
2	Can COVID-19 vaccines relieve severe tension-type headache and migraine?. Medical Hypotheses, 2022, 161, 110812.	0.8	3
3	Machine learning and semi-targeted lipidomics identify distinct serum lipid signatures in hospitalized COVID-19-positive and COVID-19-negative patients. Metabolism: Clinical and Experimental, 2022, 131, 155197.	1.5	33
4	PO-1450 Clinical Outcome and Radiologic Changes in SARS-CoV-2 Pneumonia treated with Low-Dose Radiotherapy Radiotherapy and Oncology, 2022, 170, S1229-S1231.	0.3	0
5	Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia. Antioxidants, 2022, 11, 1184.	2.2	6
6	Usefulness of the Measurement of Serum Paraoxonase-1 Arylesterase Activity in the Diagnoses of COVID-19. Biomolecules, 2022, 12, 879.	1.8	3
7	Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2022, 23, 7830.	1.8	4
8	Influence of Surgical Procedures on Serum Paraoxonase-1-Related Variables and Markers of Inflammation in Hospitalized Patients. Journal of Investigative Surgery, 2021, 34, 216-224.	0.6	11
9	Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet. Journal of Nutritional Biochemistry, 2021, 89, 108559.	1.9	15
10	Betanin and Peripheral Artery Vasospasm. Journal of Investigative Surgery, 2021, 34, 214-215.	0.6	0
11	Laparoscopic sleeve gastrectomy alters 1H-NMR-measured lipoprotein and glycoprotein profile in patients with severe obesity and nonalcoholic fatty liver disease. Scientific Reports, 2021, 11, 1343.	1.6	6
12	Paraoxonase-1 and -3 Protein Expression in the Brain of the Tg2576 Mouse Model of Alzheimer's Disease. Antioxidants, 2021, 10, 339.	2.2	14
13	Nonalcoholic Steatohepatitis Modifies Serum Iron-Related Variables in Patients with Morbid Obesity. Biological Trace Element Research, 2021, 199, 4555-4563.	1.9	6
14	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. Biomolecules, 2021, 11, 473.	1.8	10
15	First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. PLoS ONE, 2021, 16, e0248029.	1.1	206
16	Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy. PLoS ONE, 2021, 16, e0250453.	1.1	12
17	TEMPORARY REMOVAL: Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression. Journal of Hepatology, 2021, , .	1.8	3
18	Clinical Performance of Paraoxonase-1-Related Variables and Novel Markers of Inflammation in Coronavirus Disease-19. A Machine Learning Approach. Antioxidants, 2021, 10, 991.	2.2	14

#	Article	IF	CITATIONS
19	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 2021, 14, 559.	1.7	14
20	On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update. Biomolecules, 2021, 11, 971.	1.8	21
21	Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers, 2021, 13, 4009.	1.7	15
22	PO-1107 Inflammatory markers in breast cancer patients treated with radiotherapy: Machine Learning approach. Radiotherapy and Oncology, 2021, 161, S921-S922.	0.3	0
23	Clinical performance of the Elecsys \hat{A}^{\otimes} anti-SARS-CoV-2 combined in an algorithm with two specific anti-lgG immunoassays for the evaluation of the serological response of patients with COVID-19 in a population with a high prevalence of infection. Annals of Clinical Biochemistry, 2021, 58, 614-621.	0.8	1
24	Phenotypic, morphological, and metabolic characterization of vascularâ€spheres from human vascular mesenchymal stem cells. Microscopy Research and Technique, 2021, , .	1.2	3
25	Trace elements under the spotlight: A powerful nutritional tool in cancer. Journal of Trace Elements in Medicine and Biology, 2021, 68, 126858.	1.5	11
26	Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy. Clinical and Translational Oncology, 2020, 22, 1078-1085.	1.2	5
27	Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. Cytokine, 2020, 126, 154923.	1.4	11
28	Plasma metabolic alterations in patients with severe obesity and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 374-387.	1.9	20
29	Alterations in plasma concentrations of energy-balance-related metabolites in patients with lung, or head & neck, cancers: Effects of radiotherapy. Journal of Proteomics, 2020, 213, 103605.	1.2	10
30	Chemokine C–C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice. Scientific Reports, 2020, 10, 11954.	1.6	13
31	Quercetin metabolites from Hibiscus sabdariffa contribute to alleviate glucolipotoxicity-induced metabolic stress in vitro. Food and Chemical Toxicology, 2020, 144, 111606.	1.8	11
32	Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain. PLoS ONE, 2020, 15, e0234452.	1.1	41
33	The lipid composition of the liver: assessing differences in obese patients with and without non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, S654-S655.	1.8	0
34	Sex differences of adipose tissue dynamic changes in NASH progression of morbid obese patients: a preliminary study. Journal of Hepatology, 2020, 73, S662-S663.	1.8	0
35	The influence of obesity, non-alcoholic steatohepatitis and bariatric surgery on plasma lipid profile. Journal of Hepatology, 2020, 73, S664-S665.	1.8	0
36	Obesity and non-alcoholic steatohepatitis: assessing lipid diversity in adipose tissue. Journal of Hepatology, 2020, 73, S675-S676.	1.8	0

#	Article	IF	CITATIONS
37	Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform. Theranostics, 2020, 10, 3022-3034.	4.6	23
38	Systemic overexpression of C-C motif chemokine ligand 2 promotes metabolic dysregulation and premature death in mice with accelerated aging. Aging, 2020, 12, 20001-20023.	1.4	5
39	Title is missing!. , 2020, 15, e0234452.		0
40	Title is missing!. , 2020, 15, e0234452.		0
41	Title is missing!. , 2020, 15, e0234452.		0
42	Title is missing!. , 2020, 15, e0234452.		0
43	Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism: Clinical and Experimental, 2019, 99, 81-89.	1.5	43
44	Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy. Antioxidants, 2019, 8, 213.	2.2	14
45	Revisiting silibinin as a novobiocin-like Hsp90†C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology, 2019, 132, 110645.	1.8	16
46	FRI-322-Metabolic inflammation: The role of chemokine C-C motif ligan 2 in the crosstalk between liver tissue and muscle. Journal of Hepatology, 2019, 70, e537-e538.	1.8	1
47	Effect of Vitamin D3 on the Postprandial Lipid Profile in Obese Patients: A Non-Targeted Lipidomics Study. Nutrients, 2019, 11, 1194.	1.7	21
48	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	1.8	15
49	Stratification of cancer and diabetes based on circulating levels of formate and glucose. Cancer & Metabolism, 2019, 7, 3.	2.4	23
50	Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. Cell, 2019, 177, 881-895.e17.	13.5	209
51	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. Frontiers in Oncology, 2019, 9, 193.	1.3	17
52	Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1555-1566.	1.8	13
53	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	1.8	32
54	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	1.0	12

#	Article	IF	Citations
55	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	1.3	14
56	Versatile Electroanalytical Bioplatforms for Simultaneous Determination of Cancer-Related DNA 5-Methyl- and 5-Hydroxymethyl-Cytosines at Global and Gene-Specific Levels in Human Serum and Tissues. ACS Sensors, 2019, 4, 227-234.	4.0	56
57	Different behavior of polyphenols in energy metabolism of lipopolysaccharide-stimulated cells. Food Research International, 2019, 118, 96-100.	2.9	8
58	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	1.4	25
59	In silico clinical trials for anti-aging therapies. Aging, 2019, 11, 6591-6601.	1.4	3
60	Serum concentrations of trace elements and their relationships with paraoxonase-1 in morbidly obese women. Journal of Trace Elements in Medicine and Biology, 2018, 48, 8-15.	1.5	12
61	Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease. Journal of Vascular Surgery, 2018, 68, 1135-1142.e6.	0.6	7
62	Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology, 2018, 116, 161-172.	1.8	52
63	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	1.3	53
64	Serum Paraoxonase-1 Concentration as a Potential Predictor of Urinary Bladder Cancer Recurrence. A Five Year Follow-Up Study. Archives of Medical Research, 2018, 49, 119-122.	1.5	9
65	Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 127, 6-14.	2.0	32
66	Trace Elements and Paraoxonase-1 Activity in Lower Extremity Artery Disease. Biological Trace Element Research, 2018, 186, 74-84.	1.9	13
67	Novel circulating biomarkers for nonâ€alcoholic fatty liver disease: A systematic review. Journal of Cellular Physiology, 2018, 233, 849-855.	2.0	13
68	Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. Oncogene, 2018, 37, 963-970.	2.6	85
69	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget, 2018, 9, 35687-35704.	0.8	55
70	Metabolite normalization with local radiotherapy following breast tumor resection. PLoS ONE, 2018, 13, e0207474.	1.1	14
71	Trace element concentrations in breast cancer patients. Breast, 2018, 42, 142-149.	0.9	17
72	Bariatric surgery reverses dna methylation modifiyng one carbon metabolism. Atherosclerosis, 2018, 275, e76-e77.	0.4	0

#	Article	IF	CITATIONS
73	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	1.5	85
74	Plant-Derived Polyphenols in Human Health: Biological Activity, Metabolites and Putative Molecular Targets. Current Drug Metabolism, 2018, 19, 351-369.	0.7	42
75	Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	8
76	The multifactorial pathogenesis of nonalcoholic fatty liver disease: connecting inflammation and oxidation. Journal of Hepatology, 2018, 68, S340.	1.8	0
77	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	3.0	58
78	Effect of continuous renal-replacement therapy on paraoxonase-1-related variables in patients with acute renal failure caused by septic shock. Clinical Biochemistry, 2018, 61, 1-6.	0.8	4
79	Abstract P1-10-01: Safety and efficacy of neoadjuvant metformin with trastuzumab and chemotherapy in women with HER2-positive early breast cancer: A randomized, open-label, multicenter, phase 2 trial. Cancer Research, 2018, 78, P1-10-01-P1-10-01.	0.4	2
80	Treating atherosclerosis: targeting risk factors should not be the only option. Annals of Translational Medicine, 2018, 6, S34-S34.	0.7	2
81	Paraoxonases and infectious diseases. Clinical Biochemistry, 2017, 50, 804-811.	0.8	38
82	Palmitate Conditions Macrophages for Enhanced Responses toward Inflammatory Stimuli via JNK Activation. Journal of Immunology, 2017, 199, 3858-3869.	0.4	57
83	Non-invasive evaluation of extracellular matrix remodeling in peripheral artery disease. Atherosclerosis, 2017, 263, e68.	0.4	0
84	Metabolite profiling can change health-care delivery to obese patients with fatty liver disease: the search for biomarkers. Clinical Chemistry and Laboratory Medicine, 2017, 55, 501-506.	1.4	4
85	An Electrochemical Enzyme Biosensor for 3-Hydroxybutyrate Detection Using Screen-Printed Electrodes Modified by Reduced Graphene Oxide and Thionine. Biosensors, 2017, 7, 50.	2.3	34
86	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. International Journal of Molecular Sciences, 2017, 18, 2263.	1.8	18
87	Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. Nutrients, 2017, 9, 121.	1.7	33
88	Multi-Targeted Molecular Effects of Hibiscus sabdariffa Polyphenols: An Opportunity for a Global Approach to Obesity. Nutrients, 2017, 9, 907.	1.7	55
89	Cocoa and Grape Seed Byproducts as a Source of Antioxidant and Anti-Inflammatory Proanthocyanidins. International Journal of Molecular Sciences, 2017, 18, 376.	1.8	85
90	Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients. PLoS ONE, 2017, 12, e0188633.	1.1	19

#	Article	IF	Citations
91	Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. International Journal of Molecular Sciences, 2017, 18, 973.	1.8	33
92	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	0.8	9
93	Inflammation, mitochondrial metabolism and nutrition: the multi-faceted progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2016, 5, 438-443.	0.7	10
94	A preliminary study of paraoxonase-1 in infected patients with an indwelling central venous catheter. Clinical Biochemistry, 2016, 49, 449-457.	0.8	13
95	Paraoxonases, mitochondrial dysfunction and non-communicable diseases. Chemico-Biological Interactions, 2016, 259, 382-387.	1.7	20
96	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. Food and Chemical Toxicology, 2016, 96, 191-204.	1.8	27
97	Biochemical indices of oxidative stress and inflammation in the evaluation of peripheral artery disease. Free Radical Biology and Medicine, 2016, 97, 568-576.	1.3	26
98	Inferring propagation paths for sparsely observed perturbations on complex networks. Science Advances, 2016, 2, e1501638.	4.7	7
99	Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle, 2016, 15, 3355-3361.	1.3	17
100	Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1417-1424.	1.3	17
101	Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism: Clinical and Experimental, 2016, 65, 609-622.	1.5	14
102	Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports, 2016, 6, 273-283.	2.3	34
103	Exploring the effects of the atherosclerosis progression and the choice of affected arteries in the design of experiments with Apolipoprotein E-deficient mice. Cl \tilde{A} nica E Investigaci \tilde{A} 3n En Arteriosclerosis, 2016, 28, 82-86.	0.4	0
104	Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. Annals of the Rheumatic Diseases, 2016, 75, 2157-2165.	0.5	35
105	Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice. Chemico-Biological Interactions, 2016, 249, 56-63.	1.7	2
106	Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. Journal of the American Society for Mass Spectrometry, 2016, 27, 168-177.	1.2	35
107	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. Aging, 2016, 8, 1330-1352.	1.4	70
108	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience, 2016, 2, 958-967.	0.9	30

#	Article	IF	CITATIONS
109	Metformin and cancer: <i>Quo vadis et cui bono?</i> . Oncotarget, 2016, 7, 54096-54101.	0.8	15
110	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget, 2016, 7, 11959-11971.	0.8	9
111	Germline <i>BRCA1</i> mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation―strategies in <i>BRCA1</i> carriers. Oncotarget, 2016, 7, 52974-52992.	0.8	26
112	Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2. Current Clinical Pharmacology, 2016, 11, 250-258.	0.2	8
113	The impact of polyphenols on chondrocyte growth and survival: a preliminary report. Food and Nutrition Research, 2015, 59, 29311.	1.2	1
114	Immunohistochemical Analysis of Paraoxonases and Chemokines in Arteries of Patients with Peripheral Artery Disease. International Journal of Molecular Sciences, 2015, 16, 11323-11338.	1.8	23
115	Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: A transcriptomic and metabolomic study. Food and Chemical Toxicology, 2015, 77, 22-33.	1.8	38
116	The Promiscuous and Synergic Molecular Interaction of Polyphenols in Bactericidal Activity: An Opportunity to Improve the Performance of Antibiotics?. Phytotherapy Research, 2015, 29, 466-473.	2.8	34
117	The acute impact of polyphenols from Hibiscus sabdariffa in metabolic homeostasis: an approach combining metabolomics and gene-expression analyses. Food and Function, 2015, 6, 2957-2966.	2.1	25
118	Reshaping of Human Macrophage Polarization through Modulation of Glucose Catabolic Pathways. Journal of Immunology, 2015, 195, 2442-2451.	0.4	87
119	Expression of functional and silent receptors of CCL2 in human coronary arteries. Atherosclerosis, 2015, 241, e91-e92.	0.4	1
120	Lemon verbena (Lippia citriodora) polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms. Phytomedicine, 2015, 22, 605-614.	2.3	61
121	Managing Hypertension by Polyphenols. Planta Medica, 2015, 81, 624-629.	0.7	18
122	Exercise in a hot environment influences plasma anti-inflammatory and antioxidant status in well-trained athletes. Journal of Thermal Biology, 2015, 47, 91-98.	1.1	31
123	Duodeno-Jejunal Tube Placement in an Experimental Model of Obesity: Effects on Food Behaviour and Basal Energy Expenditure. Obesity Surgery, 2015, 25, 55-63.	1.1	2
124	Mapping of the circulating metabolome reveals \hat{l} ±-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. International Journal of Obesity, 2015, 39, 279-287.	1.6	77
125	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	0.8	53
126	Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World Journal of Gastroenterology, 2015, 21, 2875.	1.4	8

#	Article	IF	CITATIONS
127	Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World Journal of Gastroenterology, 2015, 21, 7529.	1.4	35
128	Paraoxonases and Chemokine (C–C Motif) Ligand-2 in Noncommunicable Diseases. Advances in Clinical Chemistry, 2014, 63, 247-308.	1.8	32
129	Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities. Vascular Medicine, 2014, 19, 442-451.	0.8	11
130	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle, 2014, 13, 1132-1144.	1.3	57
131	Exploring the Role of Paraoxonases in the Pathogenesis of Coronary Artery Disease: A Systematic Review. International Journal of Molecular Sciences, 2014, 15, 20997-21010.	1.8	38
132	Autophagy Is an Inflammation-Related Defensive Mechanism Against Disease. Advances in Experimental Medicine and Biology, 2014, 824, 43-59.	0.8	34
133	<i>Hibiscus sabdariffa</i> extract lowers blood pressure and improves endothelial function. Molecular Nutrition and Food Research, 2014, 58, 1374-1378.	1.5	52
134	Energy Metabolism and Metabolic Sensors in Stem Cells: The Metabostem Crossroads of Aging and Cancer. Advances in Experimental Medicine and Biology, 2014, 824, 117-140.	0.8	24
135	Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites. Cell Cycle, 2014, 13, 699-709.	1.3	33
136	CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile. Journal of Immunology, 2014, 192, 3858-3867.	0.4	364
137	Polyphenols and the Modulation of Gene Expression Pathways: Can We Eat Our Way Out of the Danger of Chronic Disease?. Critical Reviews in Food Science and Nutrition, 2014, 54, 985-1001.	5.4	91
138	Molecular Promiscuity of Plant Polyphenols in the Management of Age-Related Diseases: Far Beyond Their Antioxidant Properties. Advances in Experimental Medicine and Biology, 2014, 824, 141-159.	0.8	77
139	Rosiglitazone and Fenofibrate Exacerbate Liver Steatosis in a Mouse Model of Obesity and Hyperlipidemia. A Transcriptomic and Metabolomic Study. Journal of Proteome Research, 2014, 13, 1731-1743.	1.8	43
140	On the use of inexact, pruned hardware in atmospheric modelling. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2014, 372, 20130276.	1.6	25
141	Treat-to-Target Low-Density Lipoprotein Cholesterol. Angiology, 2014, 65, 261-262.	0.8	1
142	Association Between rs2200733 and rs7193343 Genetic Variants and Atrial Fibrillation in a Spanish Population, and Meta-analysis of Previous Studies. Revista Espanola De Cardiologia (English Ed), 2014, 67, 822-829.	0.4	9
143	Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway. Methods in Molecular Biology, 2014, 1170, 113-144.	0.4	108
144	Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. Aging, 2014, 6, 731-741.	1.4	29

#	Article	IF	Citations
145	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget, 2014, 5, 1942-1954.	0.8	14
146	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	0.8	40
147	A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. AIDS Research and Therapy, 2013, 10, 11.	0.7	12
148	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	1.8	53
149	Comprehensive characterization by UHPLC-ESI-Q-TOF-MS from an Eryngium bourgatii extract and their antioxidant and anti-inflammatory activities. Food Research International, 2013, 50, 197-204.	2.9	93
150	Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clinical Biochemistry, 2013, 46, 1830-1836.	0.8	46
151	Multifunctional targets of dietary polyphenols in disease: A case for the chemokine network and energy metabolism. Food and Chemical Toxicology, 2013, 51, 267-279.	1.8	55
152	Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic Approach. Journal of Proteome Research, 2013, 12, 1946-1955.	1.8	54
153	Phenolic characterization and geographical classification of commercial Arbequina extra-virgin olive oils produced in southern Catalonia. Food Research International, 2013, 50, 401-408.	2.9	95
154	Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection. Medical Hypotheses, 2013, 81, 125-130.	0.8	6
155	The mitochondrial H ⁺ -ATP synthase and the lipogenic switch. Cell Cycle, 2013, 12, 207-218.	1.3	77
156	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle, 2013, 12, 1166-1179.	1.3	146
157	Exploring PPAR Modulation in Experimental Mice. Methods in Molecular Biology, 2013, 952, 253-273.	0.4	2
158	Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes, 2013, 6, 306.	0.6	21
159	Paraoxonase-1 Is Associated With Corneal Endothelial Cell Alterations in Patients With Chronic Obstructive Pulmonary Disease. , 2013, 54, 5852.		17
160	Paraoxonase-1 status in patients with hereditary hemochromatosis. Journal of Lipid Research, 2013, 54, 1484-1492.	2.0	20
161	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports, 2013, 3, 2469.	1.6	97
162	Paraoxonase-1 Inhibits Oxidized Low-Density Lipoprotein-Induced Metabolic Alterations and Apoptosis in Endothelial Cells: A Nondirected Metabolomic Study. Mediators of Inflammation, 2013, 2013, 1-9.	1.4	29

#	Article	IF	CITATIONS
163	Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	116
164	Ubiquitous Transgenic Overexpression of C-C Chemokine Ligand 2: A Model to Assess the Combined Effect of High Energy Intake and Continuous Low-Grade Inflammation. Mediators of Inflammation, 2013, 2013, 1-19.	1.4	13
165	The relevance of the association between inflammation and atrial fibrillation. European Journal of Clinical Investigation, 2013, 43, 324-331.	1.7	27
166	Metformin: a cheap and wellâ€tolerated drug that provides benefits for viral infections. HIV Medicine, 2013, 14, 233-240.	1.0	16
167	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. Cell Cycle, 2013, 12, 555-578.	1.3	131
168	Stem cell-like ALDH ^{bright} cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	1.3	65
169	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	1.6	67
170	One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. Aging, 2013, 4, 894-898.	1.4	20
171	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget, 2013, 4, 1484-1495.	0.8	31
172	The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients. Mediators of Inflammation, 2012, 2012, 1-9.	1.4	5
173	Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation. Journal of Lipid Research, 2012, 53, 168-174.	2.0	15
174	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle, 2012, 11, 1235-1246.	1.3	56
175	PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. PPAR Research, 2012, 2012, 1-10.	1.1	43
176	Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1409-15.	1.4	20
177	Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle, 2012, 11, 2782-2792.	1.3	116
178	Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. Atherosclerosis, 2012, 220, 545-551.	0.4	24
179	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11, 865-870.	1.3	37
180	Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 894-899.	1.1	117

#	ARTICLE	IF	CITATIONS
181	Phenolic Secoiridoids in Extra Virgin Olive Oil Impede Fibrogenic and Oncogenic Epithelial-to-Mesenchymal Transition: Extra Virgin Olive Oil As a Source of Novel Antiaging Phytochemicals. Rejuvenation Research, 2012, 15, 3-21.	0.9	36
182	Bioavailability study of a polyphenolâ€enriched extract from <i><scp>H</scp>ibiscus sabdariffa</i> in rats and associated antioxidant status. Molecular Nutrition and Food Research, 2012, 56, 1590-1595.	1.5	58
183	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging, 2012, 4, 480-498.	1.4	104
184	Synergism of plant-derived polyphenols in adipogenesis: Perspectives and implications. Phytomedicine, 2012, 19, 253-261.	2.3	122
185	The Level of DING Proteins Is Increased in HIV-Infected Patients: In Vitro and In Vivo Studies. PLoS ONE, 2012, 7, e33062.	1.1	7
186	Human Duffy blood group alloantigen system influences the measurement of monocyte chemoattractant protein-1 (MCP-1) in serum but not in plasma. Clinical Laboratory, 2012, 58, 185-8.	0.2	7
187	Paraoxonases as Potential Antibiofilm Agents: Their Relationship with Quorum-Sensing Signals in Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2011, 55, 1325-1331.	1.4	67
188	Quantification of the polyphenolic fraction and in vitro antioxidant and in vivo anti-hyperlipemic activities of Hibiscus sabdariffa aqueous extract. Food Research International, 2011, 44, 1490-1495.	2.9	95
189	Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis. Journal of Clinical Virology, 2011, 51, 199-201.	1.6	19
190	Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. Clinical Biochemistry, 2011, 44, 1320-1324.	0.8	16
191	Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.	0.8	263
192	Gerosuppressant Metformin: less is more. Aging, 2011, 3, 348-362.	1.4	56
193	Paraoxonaseâ€1 is only present in traceable amounts in seminal fluid and does not show any relationship with male subfertility. BJU International, 2011, 108, 566-570.	1.3	11
194	Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. European Journal of Clinical Investigation, 2011, 41, 308-314.	1.7	48
195	Continuous administration of polyphenols from aqueous rooibos (Aspalathus linearis) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. Phytomedicine, 2011, 18, 414-424.	2.3	79
196	Identification of phenolic compounds in aqueous and ethanolic rooibos extracts (Aspalathus) Tj ETQq0 0 0 rgBT	/Oyerlock	10 Tf 50 142
197	Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. BMC Medical Genetics, 2011, 12, 120.	2.1	9
198	First Human Isolate of Mycobacterium poriferae in the Sputum of a Patient with Chronic Bronchitis. Journal of Clinical Microbiology, 2011, 49, 3107-3108.	1.8	5

#	Article	lF	Citations
199	Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. International Journal of Oncology, 2011, 38, 1533-47.	1.4	28
200	Paraoxonase-1 and clopidogrel efficacy. Nature Medicine, 2011, 17, 1041-1042.	15.2	30
201	Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. Journal of Lipid Research, 2011, 52, 1055-1061.	2.0	21
202	Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. Aging, 2011, 3, 1063-1077.	1.4	70
203	The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease. Current Molecular Medicine, 2011, 11, 453-464.	0.6	18
204	Differential response of two models of genetically modified mice fed with high fat and cholesterol diets: relationship to the study of non-alcoholic steatohepatitis. Molecular and Cellular Biochemistry, 2010, 343, 59-66.	1.4	13
205	Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. Journal of Molecular Histology, 2010, 41, 379-386.	1.0	46
206	The aqueous extract of Hibiscus sabdariffa calices modulates the production of monocyte chemoattractant protein-1 in humans. Phytomedicine, 2010, 17, 186-191.	2.3	85
207	Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life, 2010, 62, 480-482.	1.5	53
208	Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. BMC Gastroenterology, 2010, 10, 92.	0.8	18
209	Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIVâ€infected patients: relationships with serum markers of oxidation and inflammation. HIV Medicine, 2010, 11, 225-231.	1.0	89
210	Pitfalls in measuring highâ€density lipoprotein cholesterol concentrations in HIVâ€infected patients. HIV Medicine, 2010, 11, 260-265.	1.0	0
211	Paraoxonaseâ€1 Gene Haplotypes Are Associated with Metabolic Disturbances, Atherosclerosis, and Immunologic Outcome in HIVâ€Infected Patients. Journal of Infectious Diseases, 2010, 201, 627-634.	1.9	24
212	Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. Clinical Chemistry and Laboratory Medicine, 2010, 48, 893-4.	1.4	11
213	Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1147-52.	1.4	12
214	Metformin against $TGF\hat{1}^2$ -induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle, 2010, 9, 4461-4468.	1.3	202
215	Insulin Resistance, Inflammation, and Obesity: Role of Monocyte Chemoattractant Protein-1 (orCCL2) in the Regulation of Metabolism. Mediators of Inflammation, 2010, 2010, 1-11.	1.4	108
216	Dilated aortic root is related to a global aortic dilating diathesis. Journal of Vascular Surgery, 2010, 52, 867-871.	0.6	12

#	Article	IF	CITATIONS
217	Expression of cytokine genes in the aorta is altered by the deficiency in MCP-1: Effect of a high-fat, high-cholesterol diet. Cytokine, 2010, 50, 121-128.	1.4	20
218	Host–pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants. Cytokine, 2010, 51, 251-258.	1.4	11
219	Paraoxonase-1 in female infertility: a possible role against oxidative stress–induced inflammation. Fertility and Sterility, 2010, 94, 1132-1134.	0.5	12
220	Metabolomic Assessment of the Effect of Dietary Cholesterol in the Progressive Development of Fatty Liver Disease. Journal of Proteome Research, 2010, 9, 2527-2538.	1.8	141
221	Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids in Health and Disease, 2010, 9, 46.	1.2	32
222	Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. Lipids in Health and Disease, 2010, 9, 32.	1,2	11
223	Interrelationships Between Paraoxonase-1 and Monocyte Chemoattractant Protein-1 in the Regulation of Hepatic Inflammation. Advances in Experimental Medicine and Biology, 2010, 660, 5-18.	0.8	17
224	Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World Journal of Gastroenterology, 2009, 15, 1929.	1.4	45
225	The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 83-106.	2.7	215
226	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1097-9.	1.4	7
227	Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity. Mini-Reviews in Medicinal Chemistry, 2009, 9, 911-920.	1.1	32
228	Direct characterization of aqueous extract of <i>Hibiscus sabdariffa</i> using HPLC with diode array detection coupled to ESI and ion trap MS. Journal of Separation Science, 2009, 32, 3441-3448.	1.3	93
229	The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clinical Biochemistry, 2009, 42, 91-98.	0.8	59
230	Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology, 2009, 9, 3.	0.8	83
231	Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes. AIDS Research and Therapy, 2009, 6, 26.	0.7	3
232	Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine, 2009, 48, 273-279.	1.4	48
233	Metabolic phenotyping of genetically modified mice: An NMR metabonomic approachâ ⁺ †. Biochimie, 2009, 91, 1053-1057.	1.3	23
234	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. American Journal of Physiology - Renal Physiology, 2009, 296, G553-G562.	1.6	66

#	Article	IF	Citations
235	Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats. Molecular and Cellular Biochemistry, 2008, 308, 101-109.	1.4	10
236	Serum Paraoxonase Undergoes Inhibition and Proteolysis During Experimental Acute Pancreatitis. Journal of Gastrointestinal Surgery, 2008, 12, 891-899.	0.9	22
237	Selective extraction, separation, and identification of anthocyanins from <i>Hibiscus sabdariffa</i> L. using solid phase extractionâ€capillary electrophoresisâ€mass spectrometry (timeâ€ofâ€flight /ion trap). Electrophoresis, 2008, 29, 2852-2861.	1.3	72
238	Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radical Biology and Medicine, 2008, 45, 146-157.	1.3	162
239	Paraoxonase-1 in Chronic Liver Diseases, Neurological Diseases and HIV Infection., 2008, , 187-198.		7
240	Paraoxonase 1 and Postprandial Lipemia. , 2008, , 129-138.		0
241	Intermediate levels of paraoxonase-1 activity are associated to lower intima-media thickness in HIV-infected patients. Atherosclerosis, 2008, 199, 232.	0.4	0
242	Moderately High Folic Acid Supplementation Exacerbates Experimentally Induced Liver Fibrosis in Rats. Experimental Biology and Medicine, 2008, 233, 38-47.	1.1	14
243	Monocyte chemoattractant protein-1 and atherosclerosis: Is there room for an additional biomarker?. Clinica Chimica Acta, 2007, 383, 21-29.	0.5	77
244	Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment. Clinica Chimica Acta, 2007, 386, 114-115.	0.5	18
245	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 2007, 194, 175-181.	0.4	62
246	The results in rodent models of atherosclerosis are not interchangeable. Atherosclerosis, 2007, 195, e85-e92.	0.4	55
247	The Role of Immunity and Inflammation in the Progression of Atherosclerosis in Patients With HIV Infection. Stroke, 2007, 38, 2477-2484.	1.0	72
248	Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clinical Biochemistry, 2007, 40, 645-650.	0.8	55
249	ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN β AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASEâ€₄ ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 347-349.	0.9	25
250	Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Experimental and Molecular Pathology, 2007, 83, 361-366.	0.9	26
251	Experimentos con ratones susceptibles a arteriosclerosis. Ventajas, inconvenientes y aspectos que considerar. ClÃnica E Investigación En Arteriosclerosis, 2006, 18, 155-163.	0.4	1
252	Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis, 2006, 186, 152-159.	0.4	24

#	Article	IF	Citations
253	Functional and Structural Markers of Atherosclerosis in Human Immunodeficiency Virus-Infected Patients. Journal of the American College of Cardiology, 2006, 47, 1117-1123.	1.2	100
254	The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clinica Chimica Acta, 2006, 368, 114-119.	0.5	36
255	Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochemical and Biophysical Research Communications, 2006, 340, 1078-1084.	1.0	53
256	HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: The role of monocyte chemoattractant protein-1. Cytokine, 2006, 34, 51-55.	1.4	46
257	Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: A possible role for interleukin-6. Cytokine, 2006, 34, 224-232.	1.4	16
258	Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. Journal of Hepatology, 2006, 45, 51-59.	1.8	82
259	Influence of PON1 Polymorphisms on the Association between Serum Paraoxonase 1 and Homocysteinemia in a General Population. Clinical Chemistry, 2006, 52, 781-782.	1.5	9
260	ROSIGLITAZONE MODULATES FASTING AND POST-PRANDIAL PARAOXONASE 1 ACTIVITY IN TYPE 2 DIABETIC PATIENTS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1134-1137.	0.9	33
261	Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy. HIV Medicine, 2006, 7, 356-360.	1.0	6
262	New variants in the mitochondrial genomes of schizophrenic patients. European Journal of Human Genetics, 2006, 14, 520-528.	1.4	62
263	Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology, 2006, 544, 104-110.	1.7	40
264	Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy. Clinical Chemistry and Laboratory Medicine, 2006, 44, 880-2.	1.4	15
265	The stromal derived factor-1 mutated allele (SDF1-3′A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. Aids, 2005, 19, 1877-1883.	1.0	20
266	Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy. Annals of Internal Medicine, 2005, 143, 337.	2.0	114
267	Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. Translational Research, 2005, 145, 41-46.	2.4	63
268	The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clinical Biochemistry, 2005, 38, 1138-1140.	0.8	30
269	Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Molecular and Cellular Biochemistry, 2005, 268, 53-58.	1.4	72
270	Hookworm Infection. New England Journal of Medicine, 2005, 352, 205-205.	13.9	2

#	Article	IF	CITATIONS
271	Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples. Clinical Chemistry, 2005, 51, 922-923.	1.5	14
272	Evaluation of a high-sensitivity turbidimetric immunoassay for serum C-reactive protein: application to the study of longitudinal changes throughout normal pregnancy. Clinical Chemistry and Laboratory Medicine, 2005, 43, 308-13.	1.4	10
273	Preliminary evaluation of the Iris IQâ,,¢ 200 automated urine analyser. Clinical Chemistry and Laboratory Medicine, 2005, 43, 967-70.	1.4	22
274	Turpentine-induced inflammation reduces the hepatic expression of the multiple drug resistance gene, the plasma cholesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1733, 192-198.	1.2	22
275	Soluble transferrin receptor and mutations in hemochromatosis and transferrin genes in a general Catalan population. Clinica Chimica Acta, 2005, 353, 205-208.	0.5	4
276	Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clinica Chimica Acta, 2005, 361, 206-210.	0.5	35
277	Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1169-1174.	2.5	31
278	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. Aids, 2005, 19, 341-2.	1.0	28
279	Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele. Circulation, 2004, 110, 2204-2209.	1.6	121
280	Aspirin Attenuates the Initiation but Not the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice Fed a High-Fat, High-Cholesterol Diet. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 15-19.	1.2	23
281	Circulating blood cells modulate the atherosclerotic process in apolipoprotein E-deficient mice. Metabolism: Clinical and Experimental, 2004, 53, 95-100.	1.5	15
282	Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion, 2003, 36, 822-826.	0.8	38
283	Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. Clinical Biochemistry, 2003, 36, 129-134.	0.8	14
284	Differences between Genotyping and Phenotyping Methods for Assessing Apolipoprotein(a) Size Polymorphisms. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1340-4.	1.4	0
285	The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects. Clinical Chemistry and Laboratory Medicine, 2003, 41, 517-21.	1.4	33
286	Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population. Clinical Chemistry, 2003, 49, 1491-1497.	1.5	143
287	The WFS1 (Wolfram syndrome 1) is not a major susceptibility gene for the development of psychiatric disorders. Psychiatric Genetics, 2003, 13, 29-32.	0.6	13
288	Impaired vitamin E status in patients with parenchymal liver cirrhosis: Relationships with lipoprotein compositional alterations, nutritional factors, and oxidative susceptibility of plasma. Metabolism: Clinical and Experimental, 2002, 51, 609-615.	1.5	18

#	Article	IF	CITATIONS
289	Xantoma gástrico. ClÃnica E Investigación En Arteriosclerosis, 2002, 14, 166.	0.4	0
290	El tÃtulo de anticuerpos anti-LDL oxidada no estÃ; relacionado con la actividad paraoxonasa en suero ni con sus polimorfismos genéticos en sujetos normales y en pacientes con infarto de miocardio. ClÃnica E Investigación En Arteriosclerosis, 2002, 14, 135-139.	0.4	0
291	Plasma Homocysteine Concentrations in Patients with Liver Cirrhosis. Clinical Chemistry, 2002, 48, 183-185.	1.5	19
292	Serum Paraoxonase Activity: A New Additional Test for the Improved Evaluation of Chronic Liver Damage. Clinical Chemistry, 2002, 48, 261-268.	1.5	192
293	Newly Identified Apolipoprotein AV Gene Predisposes to High Plasma Triglycerides in Familial Combined Hyperlipidemia. Clinical Chemistry, 2002, 48, 1597-1600.	1.5	121
294	Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. Translational Research, 2002, 139, 181-187.	2.4	15
295	Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clinical Biochemistry, 2002, 35, 197-203.	0.8	46
296	Plasma homocysteine concentrations in patients with liver cirrhosis. Clinical Chemistry, 2002, 48, 183-5.	1.5	4
297	Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry, 2002, 48, 261-8.	1.5	55
298	The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clinical Chemistry, 2002, 48, 372-5.	1.5	15
299	Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clinical Chemistry, 2002, 48, 1597-600.	1.5	29
300	Association study of schizophrenia with polymorphisms at six candidate genes. Schizophrenia Research, 2001, 49, 65-71.	1.1	108
301	Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism: Clinical and Experimental, 2001, 50, 997-1000.	1.5	66
302	El ratón deficiente en apolipoproteÃna E y su aplicación al estudio de la arteriosclerosis. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 162-166.	0.4	0
303	The Antioxidant and Hepato-Protective Effects of Zinc are Related to Hepatic Cytochrome P450 Depression and Metallothionein Induction in Rats with Experimental Cirrhosis. International Journal for Vitamin and Nutrition Research, 2001, 71, 229-236.	0.6	15
304	Impact of Apolipoprotein(a) Isoform Size Heterogeneity on the Lysine Binding Function of Lipoprotein(a) in Early Onset Coronary Artery Disease. Thrombosis and Haemostasis, 2001, 85, 412-417.	1.8	13
305	Instability of Lipoprotein(a) in Plasma Stored at â^'70 °C. Clinical Chemistry, 2001, 47, 1673-1678.	1.5	18
306	Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease: relationship to allele size, plasma lipoprotein(a) concentration, and lysine binding site activity. Journal of Molecular Medicine, 2001, 79, 294-299.	1.7	5

#	Article	IF	CITATIONS
307	Effects of high-fat, low-cholesterol diets on hepatic lipid peroxidation and antioxidants in apolipoprotein E-deficient mice. Molecular and Cellular Biochemistry, 2001, 218, 165-169.	1.4	32
308	Schizophrenic women with the APOE $\hat{l}\mu4$ allele have a worse prognosis than those without it. Molecular Psychiatry, 2001, 6, 307-310.	4.1	28
309	Supplementation with Vitamin E and/or Zinc does not Attenuate Atherosclerosis in Apolipoprotein E-deficient Mice fed a High-Fat, High-Cholesterol Diet. International Journal for Vitamin and Nutrition Research, 2001, 71, 45-52.	0.6	23
310	Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease. Thrombosis and Haemostasis, 2001, 85, 412-7.	1.8	7
311	Instability of lipoprotein(a) in plasma stored at -70 degrees C: effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. Clinical Chemistry, 2001, 47, 1673-8.	1.5	11
312	The value of apolipoprotein E knockout mice for studying the effects of dietary fat and cholesterol on atherogenesis. Current Opinion in Lipidology, 2000, 11, 25-29.	1.2	76
313	Time-Course Of Changes In Hepatic Lipid Peroxidation And Glutathione Metabolism In Rats With Carbon Tetrachloride-Induced Cirrhosis. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 694-699.	0.9	79
314	Evaluation of a particle-enhanced turbidimetric immunoassay for the measurement of ferritin: application to patients participating in an autologous blood transfusion program. Clinical Biochemistry, 2000, 33, 191-196.	0.8	21
315	Homocyst(e)ine and the C677T mutation of methylenetetrahydrofolate reductase in survivors of premature myocardial infarction. Clinical Biochemistry, 2000, 33, 509-512.	0.8	6
316	PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 179-184.	0.9	14
317	Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome. Journal of Molecular Medicine, 2000, 78, 147-154.	1.7	9
318	Agreement Study of Methods Based on the Elimination Principle for the Measurement of LDL- and HDL-Cholesterol Compared with Ultracentrifugation in Patients with Liver Cirrhosis. Clinical Chemistry, 2000, 46, 1188-1191.	1.5	20
319	The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sciences, 2000, 68, 457-465.	2.0	54
320	Pharmacokinetics Of Several Subcutaneous Doses Of Erythropoietin: Potential Implications For Blood Transfusion. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 179.	0.9	3
321	Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 179-84.	0.9	5
322	Agreement study of methods based on the elimination principle for the measurement of LDL- and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clinical Chemistry, 2000, 46, 1188-91.	1.5	3
323	Altered Composition of Lipoproteins in Liver Cirrhosis Compromises Three Homogeneous Methods for HDL-Cholesterol. Clinical Chemistry, 1999, 45, 685-688.	1.5	18
324	Evaluation of a Particle-enhanced Turbidimetric Immunoassay for the Measurement of Immunoglobulin E in an ILab 900 Analyzer. Clinical Chemistry, 1999, 45, 1557-1561.	1,5	4

#	Article	IF	CITATIONS
325	Low-Cholesterol and High-Fat Diets Reduce Atherosclerotic Lesion Development in ApoE-Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2368-2375.	1.1	86
326	Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis. Molecular and Cellular Biochemistry, 1999, 198, 57-60.	1.4	10
327	Anticipation is not associated with CAG repeat expansion in parent-offspring pairs of patients affected with schizophrenia., 1999, 88, 50-56.		13
328	Inhibition of hepatic cell nuclear DNA fragmentation by zinc in carbon tetrachloride-treated rats. Journal of Hepatology, 1999, 31, 228-234.	1.8	55
329	Reduced progression of atherosclerosis in apolipoprotein E-deficient mice with phenylhydrazine-induced anemia. Atherosclerosis, 1999, 147, 61-68.	0.4	27
330	Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant. NeuroReport, 1999, 10, 2035-2038.	0.6	64
331	Altered composition of lipoproteins in liver cirrhosis compromises three homogeneous methods for HDL-cholesterol. Clinical Chemistry, 1999, 45, 685-8.	1.5	2
332	Evaluation of a particle-enhanced turbidimetric immunoassay for the measurement of immunoglobulin E in an ILab 900 analyzer. Clinical Chemistry, 1999, 45, 1557-61.	1.5	3
333	Lipoprotein(a) and the significance of the association between platelet glycoprotein Illa polymorphisms and the risk of premature myocardial infarction. Atherosclerosis, 1998, 140, 155-159.	0.4	37
334	Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clinical Chemistry, 1998, 44, 1233-1241.	1.5	36
335	Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clinical Chemistry, 1998, 44, 1233-41.	1.5	13
336	Hemorheological, coagulative and fibrinolytic changes during autologous blood donation. Clinical Hemorheology and Microcirculation, 1998, 18, 265-72.	0.9	8
337	Lipoprotein alterations in liver cirrhosis: a possible contribution to changes in plasma oncotic pressure and viscosity. Journal of Hepatology, 1997, 27, 639-644.	1.8	9
338	Impact of Gender on the Metabolism of Apolipoprotein A-I in HDL Subclasses LpAI and LpAI:AII in Older Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3513-3518.	1.1	32
339	Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity. Clinical Chemistry, 1997, 43, 1223-1231.	1.5	22
340	The repeat expansion detection method in the analysis of diseases with CAG/CTG repeat expansion: Usefulness and limitations. Human Mutation, 1997, 10, 486-488.	1.1	9
341	Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity. Clinical Chemistry, 1997, 43, 1223-31.	1.5	8
342	The influence of apoprotein epsilon 2 homozygosity on nephrotic hyperlipidemia. Clinical Nephrology, 1997, 48, 141-5.	0.4	5

#	Article	IF	CITATIONS
343	Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis, 1996, 127, 273-282.	0.4	46
344	The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. Atherosclerosis, 1996, 126, 243-252.	0.4	19
345	Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clinical Chemistry, 1995, 41, 908-913.	1.5	36
346	Hyperlipidaemia of the nephrotic syndromeâ€"the search for a nephrotic factor. Nephrology Dialysis Transplantation, 1995, , .	0.4	1
347	Influence of zinc intake on hepatic lipid peroxidation and metallothioneins in alcoholic rats: relationship to collagen synthesis. International Journal for Vitamin and Nutrition Research, 1995, 65, 45-50.	0.6	17
348	Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clinical Chemistry, 1995, 41, 908-13.	1.5	6
349	Hyperlipidaemia of the nephrotic syndromethe search for a nephrotic factor. Nephrology Dialysis Transplantation, 1995, 10, 314-6.	0.4	8
350	Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clinical Chemistry, 1994, 40, 404-406.	1.5	64
351	Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clinical Chemistry, 1994, 40, 625-629.	1.5	34
352	Semiautomated determination of glycated albumin in glycaemic control of diabetic patients. Clinical Biochemistry, 1994, 27, 307-309.	0.8	2
353	Binding of Lipoprotein Lipase to ?2-Macroglobulin. Annals of the New York Academy of Sciences, 1994, 737, 510-513.	1.8	0
354	Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1994, 43, 614-620.	1.5	39
355	Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting from alcohol abuse: effects of alcohol intake cessation. Journal of Hepatology, 1994, 21, 704-709.	1.8	10
356	Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clinical Chemistry, 1994, 40, 404-6.	1.5	25
357	Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clinical Chemistry, 1994, 40, 625-9.	1.5	11
358	Lipoprotein heterogeneity in end-stage renal disease. Kidney International, 1993, 43, 410-418.	2.6	48
359	Pattern of Hyperlipoproteinemia in Human Nephrotic Syndrome: Influence of Renal Failure and Diabetes mellitus. Nephron, 1993, 64, 565-569.	0.9	11
360	Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. Journal of Lipid Research, 1993, 34, 1555-1564.	2.0	135

#	Article	IF	Citations
361	Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. Journal of Lipid Research, 1993, 34, 1555-64.	2.0	98
362	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. Clinical Science, 1992, 83, 695-700.	1.8	72
363	Serum Fructosamine Concentration in Patients with Nephrotic Syndrome and with Cirrhosis of the Liver: The Influence of Hypoalbuminaemia and Hypergammaglobulinaemia. Annals of Clinical Biochemistry, 1992, 29, 437-442.	0.8	37
364	Interaction of oxidized low density lipoproteins with both apo B,E and scavenger receptors. A model for its production in vitro. Clinica Chimica Acta, 1992, 210, 93-108.	0.5	1
365	Low density lipoprotein receptor levels and the response to dietary and pharmacological intervention in polygenic hypercholesterolemia. Clinica Chimica Acta, 1991, 197, 67-76.	0.5	3
366	Alterations in plasma lifoproteins in patients with alcoholic liver disease. Journal of Hepatology, 1991, 13, S105.	1.8	0
367	The Mediterranean-type diet: is there a need for further modification?. American Journal of Clinical Nutrition, 1991, 53, 886-889.	2.2	36
368	Serum levels of lipoprotein(a) in patients with well-controlled non-insulin-dependent diabetes mellitus. JAMA - Journal of the American Medical Association, 1991, 265, 1113-1114.	3.8	25
369	Serum levels of lipoprotein(a) in patients with well-controlled non-insulin-dependent diabetes mellitus. JAMA - Journal of the American Medical Association, 1991, 265, 1113-4.	3.8	1
370	Toxicity of Lovastatin in Rats with Experimentally Induced Nephrotic Syndrome. Nephron, 1990, 56, 399-404.	0.9	2
371	Low Density Lipoprotein Metabolism and Receptor Studies in a Patient with Pseudohomozygous Familial Hypercholesterolaemia. Acta Paediatrica, International Journal of Paediatrics, 1990, 79, 475-476.	0.7	12
372	Abnormalities of Lipoprotein Metabolism in Patients with the Nephrotic Syndrome. New England Journal of Medicine, 1990, 323, 579-584.	13.9	275
373	Possible overestimation of ultracentrifugally isolated "free" apoprotein A-I in serum. Clinical Chemistry, 1990, 36, 407.	1.5	0
374	Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes Clinical Chemistry, 1989, 35, 813-816.	1.5	47
375	LIPID-LOWERING DRUGS IN TREATMENT OF HYPERLIPIDAEMIA ASSOCIATED WITH NEPHROTIC SYNDROME. Lancet, The, 1989, 333, 1029.	6.3	1
376	Low density lipoprotein metabolism in rats with puromycin aminonucleoside-induced nephrotic syndrome. Metabolism: Clinical and Experimental, 1989, 38, 491-495.	1.5	17
377	Treatment of Dietâ€Resistant Polygenic Hypercholesterolaemic Patients with a New Nicotinate Derivative; In Vivo and In Vitro Low Density Lipoprotein Metabolic Studies. Journal of Clinical Pharmacology, 1989, 29, 201-206.	1.0	2
378	Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes. Clinical Chemistry, 1989, 35, 813-6.	1.5	9

#	Article	IF	CITATIONS
379	High-Density Lipoproteins in Untreated Idiopathic Nephrotic Syndrome Without Renal Failure. Nephrology Dialysis Transplantation, 1987, , .	0.4	3
380	High-Density Lipoprotein Cholesterol Subfractions in Chronic Uremia. American Journal of Kidney Diseases, 1987, 9, 60-65.	2.1	32
381	Potassium disturbances as a cause of metabolic neuromyopathy. Intensive Care Medicine, 1987, 13, 208-10.	3.9	14
382	High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrology Dialysis Transplantation, 1987, 2, 149-53.	0.4	9
383	Apoprotein A-I and High Density Lipoprotein Subtractions in Patients with Chronic Renal Failure Receiving Hemodialysis. Nephron, 1985, 40, 451-454.	0.9	13
384	Cryoglobulinemia and Fibronectin. Acta Haematologica, 1985, 74, 161-163.	0.7	13
385	Precipitation of Mn2+ with HCO3- in determinations of high-density lipoprotein subfractions Clinical Chemistry, 1985, 31, 340-340.	1.5	1
386	Hormonal profile and serum zinc levels in uraemic men with gonadal dysfunction undergoing haemodialysis. Clinica Chimica Acta, 1985, 148, 239-245.	0.5	27
387	High density lipoprotein changes during treatment of diabetic ketoacidosis. Diabète & Métabolisme, 1985, 11, 102-5.	0.3	1
388	Should plasma high-density lipoprotein subfractions be evaluated?. Clinical Chemistry, 1985, 31, 1095-6.	1.5	1
389	High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis and Rheumatism, 1984, 27, 1199-1200.	6.7	12